Lastly, our results suggest that the oxidative damage in MDS is related, at least in part, to signaling pathways regulating the cell cycle through p53/p21, which are moderated by DFX treatment, overall highlighting the important role of DFX in the control of the oxidative stress response in MDS. This evidence concerns the gene TP53 and myelodysplastic syndrome.